First patient dosed in Phase 1 trial for GMI-1271

|By:, SA News Editor

GlycoMimetics (GLYC +0.7%) reports that the first healthy volunteer has been dosed in a Phase 1 clinical study to evaluate the safety, tolerability and pharmacokinetics of GMI-1271, an E-selectin antagonist the company is developing for various cancers.

The single-site 28-patient trial will assess three dosages of GMI-1271. The company expects final results in 2H 2014.